Aleksandrovych V, Wrona A, Bereza T, Pitynski K, Gil K. Oviductal Telocytes in Patients with Uterine Myoma. Biomedicines. 2021;9: pubmed publisher

Erber R, Meyer J, Taubert H, Fasching P, Wach S, Haberle L, et al. PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. Cancers (Basel). 2020;12: pubmed publisher

Christgen M, Bartels S, van Luttikhuizen J, Bublitz J, Rieger L, Christgen H, et al. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Mod Pathol. 2020;33:2483-2498 pubmed publisher

Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed publisher

Winder A, Maniar K, Wei J, Liu D, Scholtens D, Lurain J, et al. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017;123:1144-1155 pubmed publisher

Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher

Sugihara T, Nakagawa S, Sasajima Y, Ichinose T, Hiraike H, Kondo F, et al. Loss of the cell polarity determinant human Discs-large is a novel molecular marker of nodal involvement and poor prognosis in endometrial cancer. Br J Cancer. 2016;114:1012-8 pubmed publisher

Carbognin L, Sperduti I, Brunelli M, Marcolini L, Nortilli R, Pilotto S, et al. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. J Exp Clin Cancer Res. 2016;35:50 pubmed publisher

Al Harras M, Houssen M, Shaker M, Farag K, Farouk O, Monir R, et al. Polymorphisms of glutathione S-transferase ? 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility. Oncol Lett. 2016;11:2182-2188 pubmed

Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher

Alkner S, Bendahl P, Ehinger A, Lövgren K, Rydén L, Fernö M. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE. 2016;11:e0150977 pubmed publisher

Cammas A, Lacroix Triki M, Pierredon S, Le Bras M, Iacovoni J, Teulade Fichou M, et al. hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget. 2016;7:16793-805 pubmed publisher

Nalwoga H, Ahmed L, Arnes J, Wabinga H, Akslen L. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS ONE. 2016;11:e0146823 pubmed publisher

Fridriksdottir A, Kim J, Villadsen R, Klitgaard M, Hopkinson B, Petersen O, et al. Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. Nat Commun. 2015;6:8786 pubmed publisher

Jung Y, Kim H, Koo J. Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer. PLoS ONE. 2015;10:e0137204 pubmed publisher

Kim H, Lee K, Park I, Chung Y, Im S, Noh D, et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Arch. 2015;467:563-70 pubmed publisher

Mundim F, Pasini F, Brentani M, Soares F, Nonogaki S, Waitzberg A. MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. Mol Clin Oncol. 2015;3:506-514 pubmed

Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, et al. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol. 2015;15:8 pubmed publisher

Michaelidou K, Ardavanis A, Scorilas A. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. Breast Cancer Res Treat. 2015;152:323-36 pubmed publisher

Nakada S, Minato H, Takegami T, Kurose N, Ikeda H, Kobayashi M, et al. NAB2-STAT6 fusion gene analysis in two cases of meningeal solitary fibrous tumor/hemangiopericytoma with late distant metastases. Brain Tumor Pathol. 2015;32:268-74 pubmed publisher

Geels Y, van der Putten L, van Tilborg A, Lurkin I, Zwarthoff E, Pijnenborg J, et al. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol. 2015;137:245-51 pubmed publisher

Eom K, Jang M, Park S, Kang E, Kim S, Kim J, et al. The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer. Cancer Res Treat. 2016;48:125-32 pubmed publisher

Rusz O, Vörös A, Varga Z, Kelemen G, Uhercsák G, Nikolényi A, et al. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer. Pathol Oncol Res. 2015;21:977-84 pubmed publisher

Kim S, Lee Y, Koo J. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE. 2015;10:e0119473 pubmed publisher

Simons M, Nagtegaal I, Overbeek L, Flucke U, Massuger L, Bulten J. A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases. Int J Gynecol Pathol. 2015;34:143-50 pubmed publisher

Argon A, Şener A, Zekioğlu O, Kapkaç M, Özdemir N. The effect of freezing on the immunoprofile of breast carcinoma cells. Balkan Med J. 2014;31:335-9 pubmed publisher

Park S, Kim H, Koo J. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat. 2015;149:727-41 pubmed publisher

Kim G, Lee J, Choi Y, Lee K, Lee J, Nam J, et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer. 2014;14:959 pubmed publisher

Panis C, Pizzatti L, Corrêa S, Binato R, Lemos G, Herrera A, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357:186-95 pubmed publisher

Baccelli I, Stenzinger A, Vogel V, Pfitzner B, Klein C, Wallwiener M, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 2014;5:8147-60 pubmed

Kuroda N, Fujishima N, Hayes M, Moritani S, Ichihara S. Encapsulated papillary carcinoma, apocrine type, of the breast. Malays J Pathol. 2014;36:139-43 pubmed

Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed publisher

Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed

Mingels M, Masadah R, Geels Y, Otte Holler I, de Kievit I, van der Laak J, et al. High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer. Am J Clin Pathol. 2014;142:213-21 pubmed publisher

Fujiwara S, Hung M, Yamamoto Ibusuk C, Yamamoto Y, Yamamoto S, Tomiguchi M, et al. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer. Oncotarget. 2014;5:3919-30 pubmed

Syed B, Green A, Nolan C, Morgan D, Ellis I, Cheung K. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. PLoS ONE. 2014;9:e100573 pubmed publisher

van der Post R, Bult P, Vogelaar I, Ligtenberg M, Hoogerbrugge N, van Krieken J. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch. 2014;464:673-9 pubmed publisher

Balk Møller E, Kim J, Hopkinson B, Timmermans Wielenga V, Petersen O, Villadsen R. A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched. Am J Pathol. 2014;184:1198-208 pubmed publisher

Park H, Jang M, Kim E, Kim H, Lee H, Kim Y, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27:1212-22 pubmed publisher

Balko J, Giltnane J, Wang K, Schwarz L, Young C, Cook R, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232-45 pubmed publisher

Faupel Badger J, Duggan M, Sherman M, Garcia Closas M, Yang X, Lissowska J, et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5:42-50 pubmed publisher

Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses K, et al. Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis. 2013;16:387-90 pubmed publisher

Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, et al. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer. 2014;134:1112-22 pubmed publisher

Yamada Y, Yamamoto H, Ohishi Y, Nishiyama K, Fukuhara M, Saitou T, et al. Sclerosing variant of perivascular epithelioid cell tumor in the female genital organs. Pathol Int. 2011;61:768-72 pubmed publisher

Roosta Y, Sanaat Z, Nikanfar A, Dolatkhah R, Fakhrjou A. Predictive Value of CD44 for Prognosis in Patients with Breast Cancer. Asian Pac J Cancer Prev. 2020;21:2561-2567 pubmed publisher

Sanges F, Floris M, Cossu Rocca P, Muroni M, Pira G, Urru S, et al. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BMC Cancer. 2020;20:491 pubmed publisher

Cipak Gašparović A, Milković L, Dandachi N, Stanzer S, Pezdirc I, Vrančić J, et al. Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype. Antioxidants (Basel). 2019;8: pubmed publisher

Pu T, Shui R, Shi J, Liang Z, Yang W, Bu H, et al. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China. BMC Cancer. 2019;19:978 pubmed publisher

Sun Y, Wang J. Primary pseudomyogenic hemangioendothelioma of the vulva: a rare location for a rare entity. Diagn Pathol. 2019;14:66 pubmed publisher

Kikuchi Koike R, Nagasaka K, Tsuda H, Ishii Y, Sakamoto M, Kikuchi Y, et al. Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. BMC Cancer. 2019;19:521 pubmed publisher

Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, et al. Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. Ann Surg Oncol. 2019;: pubmed publisher

Jacobsson H, Harrison H, Hughes E, Persson E, Rhost S, Fitzpatrick P, et al. Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways. Mol Oncol. 2019;13:1693-1705 pubmed publisher

Narbe U, Sjöström M, Forsare C, Bendahl P, Alkner S, Leeb Lundberg L, et al. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2019;175:305-316 pubmed publisher

Ohe R, Meng H, Ye Aung N, Yamada A, Kabasawa T, Utsunomiya A, et al. Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma. Hematol Oncol. 2019;37:151-159 pubmed publisher

Jevrić M, Matić I, Krivokuca A, Đorđić Crnogorac M, Besu I, Damjanovic A, et al. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. BMC Cancer. 2019;19:71 pubmed publisher

Kuroda H, Muroi N, Hayashi M, Harada O, Hoshi K, Fukuma E, et al. Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining. Breast Cancer. 2019;26:249-254 pubmed publisher

Gass P, Lux M, Rauh C, Hein A, Bani M, Fiessler C, et al. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer. 2018;18:1051 pubmed publisher

Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman K, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018;18:958 pubmed publisher

Lee K, Kim E, Yun J, Park Y, Do S, Chae S, et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018;18:938 pubmed publisher

Mise I, Vucić M. Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases. Anal Cell Pathol (Amst). 2018;2018:9432375 pubmed publisher

Hashmi A, Mahboob R, Khan S, Irfan M, Nisar M, Iftikhar N, et al. Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers. BMC Res Notes. 2018;11:574 pubmed publisher

Hashmi A, Aijaz S, Mahboob R, Khan S, Irfan M, Iftikhar N, et al. Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: comparison with invasive ductal carcinoma of breast. BMC Res Notes. 2018;11:531 pubmed publisher

Kanda R, Hiraike H, Wada Hiraike O, Ichinose T, Nagasaka K, Sasajima Y, et al. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer. 2018;18:657 pubmed publisher

Pajares B, Porta J, Porta J, Sousa C, Moreno I, Porta D, et al. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study. BMC Cancer. 2018;18:647 pubmed publisher

Mudduwa L, Peiris H, Gunasekara S, Abeysiriwardhana D, Liyanage N, Rayala S, et al. KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy. BMC Cancer. 2018;18:589 pubmed publisher

Urru S, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018;18:56 pubmed publisher

Kashiwagi S, Fukushima W, Asano Y, Goto W, Takada K, Noda S, et al. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer. BMC Cancer. 2017;17:604 pubmed publisher

van T Veer L, Yau C, Yu N, Benz C, Nordenskjold B, Fornander T, et al. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017;166:593-601 pubmed publisher

Haberle L, Hein A, Rübner M, Schneider M, Ekici A, Gass P, et al. Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. Geburtshilfe Frauenheilkd. 2017;77:667-678 pubmed publisher

Stefansson O, Hermanowicz S, van der Horst J, Hilmarsdottir H, Staszczak Z, Jonasson J, et al. CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer. BMC Cancer. 2017;17:469 pubmed publisher

Jucá P, Corrêa S, Vignal G, Accioly M, Lustosa S, Abdelhay E, et al. HNF4A expression as a potential diagnostic tool to discriminate primary gastric cancer from breast cancer metastasis in a Brazilian cohort. Diagn Pathol. 2017;12:43 pubmed publisher

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer. 2017;17:354 pubmed publisher

Delgado García S, Martínez Escoriza J, Alba A, Martín Bayón T, Ballester Galiana H, Peiró G, et al. Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study. BMC Cancer. 2017;17:320 pubmed publisher

Sinn H, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17:124 pubmed publisher

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R, et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016;167:260-274.e22 pubmed publisher

Chen S, Huang L, Chen C, Shao Z. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget. 2015;6:18174-82 pubmed

Stathopoulos G, Malamos N, Markopoulos C, Polychronis A, Armakolas A, Rigatos S, et al. The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs. 2014;25:950-7 pubmed publisher

Moberg C, Bourlev V, Ilyasova N, Olovsson M. Levels of oestrogen receptor, progesterone receptor and ?B-crystallin in eutopic endometrium in relation to pregnancy in women with endometriosis. Hum Fertil (Camb). 2015;18:30-7 pubmed publisher

Medale Giamarchi C, Lajoie Mazenc I, Malissein E, Meunier E, Couderc B, Bergé Y, et al. RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Res. 2013;15:R6 pubmed publisher

Rokicki J, Das P, Giltnane J, Wansbury O, Rimm D, Howard B, et al. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer. 2010;9:150 pubmed publisher

Loddo M, Kingsbury S, Rashid M, Proctor I, Holt C, Young J, et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer. 2009;100:959-70 pubmed publisher